{"id":16480,"date":"2023-09-13T06:53:58","date_gmt":"2023-09-13T06:53:58","guid":{"rendered":"https:\/\/lawsuitlegit.com\/?p=16480"},"modified":"2023-09-20T03:04:02","modified_gmt":"2023-09-20T03:04:02","slug":"morbidity-study-of-former-marines-employees-and-dependents-potentially-exposed-to-contaminated-drinking-water-at-u-s-marine-corps-base-camp-lejeune","status":"publish","type":"post","link":"https:\/\/lawsuitlegit.com\/morbidity-study-of-former-marines-employees-and-dependents-potentially-exposed-to-contaminated-drinking-water-at-u-s-marine-corps-base-camp-lejeune\/","title":{"rendered":"Morbidity Study of Former Marines, Employees, and Dependents Potentially Exposed to Contaminated Drinking Water at U.S. Marine Corps Base Camp Lejeune"},"content":{"rendered":"
Morbidity Study of Former Marines, Employees, and Dependents Potentially Exposed to Contaminated Drinking Water at U.S. Marine Corps Base Camp Lejeune<\/p>\n
<\/p>\n
April, 2018<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
Morbidity Study of Former Marines, Employees, and <\/strong><\/p>\n Dependents Potentially Exposed to Contaminated Drinking <\/strong><\/p>\n Water at U.S. Marine Corps Base Camp Lejeune <\/strong><\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0<\/strong><\/p>\n <\/p>\n CONTENTS <\/strong><\/p>\n EXECUTIVE SUMMARY......................................................................................................... 4 <\/a><\/p>\n Introduction............................................................................................................................. 4 <\/a><\/p>\n Methods................................................................................................................................... 4 <\/a><\/p>\n Results and Conclusion........................................................................................................... 9 <\/a><\/p>\n INTRODUCTION.................................................................................................................... 13 <\/a><\/p>\n METHODS............................................................................................................................... 16 <\/a><\/p>\n Study Hypotheses.................................................................................................................. 16 <\/a><\/p>\n Study Population and Eligibility........................................................................................... 17 <\/a><\/p>\n Data Collection...................................................................................................................... 18 <\/a><\/p>\n Exposure Assessment............................................................................................................ 21 <\/a><\/p>\n Data Analysis......................................................................................................................... 24 <\/a><\/p>\n Analysis of disease risk in Marines.......................................................................................... 25 <\/a><\/p>\n Analysis of disease risk in civilian employees......................................................................... 26 <\/a><\/p>\n Sensitivity analyses................................................................................................................... 26 <\/a><\/p>\n Interpretation of results............................................................................................................. 28 <\/a><\/p>\n Presentation of results............................................................................................................... 30 <\/a><\/p>\n RESULTS................................................................................................................................. 31 <\/a><\/p>\n Cancer.................................................................................................................................... 33 <\/a><\/p>\n Digestive organs.................................................................................................................... 33 <\/a><\/p>\n Hematopoietic........................................................................................................................ 36 <\/a><\/p>\n Respiratory............................................................................................................................ 38 <\/a><\/p>\n Sex-specific........................................................................................................................... 39 <\/a><\/p>\n Urinary................................................................................................................................... 41 <\/a><\/p>\n Other...................................................................................................................................... 42 <\/a><\/p>\n Non-cancer diseases.............................................................................................................. 44 <\/a><\/p>\n Autoimmune diseases............................................................................................................ 44 <\/a><\/p>\n Nervous system..................................................................................................................... 44 <\/a><\/p>\n Reproductive organs.............................................................................................................. 46 <\/a><\/p>\n Other...................................................................................................................................... 47 <\/a><\/p>\n Sensitivity Analyses of Marines\/Navy and Civilian Employee Cohorts............................... 49 <\/a><\/p>\n 1999-2002 ATSDR Survey Cohort........................................................................................ 50 <\/a><\/p>\n DISCUSSION........................................................................................................................... 51 <\/a><\/p>\n LIMITATIONS......................................................................................................................... 54 <\/a><\/p>\n CONCLUSIONS...................................................................................................................... 57 <\/a><\/p>\n ACKNOWLEDGEMENT........................................................................................................ 58 <\/a><\/p>\n REFERENCES......................................................................................................................... 59 <\/a><\/p>\n TABLES.................................................................................................................................... 64 <\/a><\/p>\n FIGURE 1............................................................................................................................... 105 <\/a><\/p>\n